1 July 2024 - Longboard Pharmaceuticals today announced that the FDA has granted breakthrough therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies for patients two years of age or older.

Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor sub-types, into a global Phase 3 program.

Read Longboard Pharmaceuticals press release